Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Migraine recurrence
RCT 4-armed trial	866 participants aged 12–17 years with a >1-year history of migraine; final analysis consisted of 714 (82%) participants who completed the study protocol	Proportion of participants with migraine recurrence between 2 and 24 hours 6% with almotriptan 6.25 mg 8% with almotriptan 12.5 mg 3% with almotriptan 25 mg 5% with placebo Absolute numbers not reported	P value not reported Reported as not significant for any dose of almotriptan v placebo		Not significant
RCT 4-armed trial	866 participants aged 12–17 years with a >1-year history of migraine; final analysis consisted of 714 (82%) participants who completed the study protocol	Proportion of participants using rescue medication between 2 and 24 hours 2.8% with almotriptan 6.25 mg 5.0% with almotriptan 12.5 mg 3.2% with almotriptan 25 mg 6.5% with placebo Absolute numbers not reported	P values not reported Reported as not significant for any dose of almotriptan v placebo		Not significant